A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.
Konstantin DobererMichael DuerrPhilip F HalloranFarsad EskandaryKlemens BuddeHeinz RegeleJeff ReeveAnita BorskiNicolas KozakowskiRoman Reindl-SchwaighoferJohannes WaiserNils LachmannSabine SchranzChrista FirbasJakob MühlbacherGeorg GelbeneggerThomas PerkmannMarkus WahrmannAlexander KainzRobin RistlFabian HalleckGregor BondEdward ChongBernd JilmaGeorg A BöhmigPublished in: Journal of the American Society of Nephrology : JASN (2020)
Although safety data indicate the need for careful patient selection and monitoring, our preliminary efficacy results suggest a potentially beneficial effect of clazakizumab on ABMR activity and progression.